Nipro Corporation has announced the US commercial launch of Elisio-HX, a medium-cutoff dialyser featuring super high-flux membrane technology.
Enabled by the recent US Food and Drug Administration (FDA) 510(k) clearance of the technology, Nipro is introducing its expanded haemodialysis approach with a super high-flux membrane, or HDs in short, to dialysis providers.
Nipro says that the membrane incorporates a highly controlled and precisely engineered pore structure designed to extend the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients’ nutritional status.
Since the Elisio-HX is compatible with existing haemodialysis infrastructure, physicians and providers can incorporate expanded haemodialysis into routine clinical practice without purchasing new machines, fundamentally changing treatment workflows or retraining staff, the company says in a press release.
“Providers have sought a scalable way to improve middle-molecule clearance, but supply constraints, operational complexity and infrastructure requirements have impacted adoption rates in the USA,” said James McGetrick, president of North America for Nipro Medical Corporation. “The Elisio-HX is designed to help overcome those barriers, making this approach accessible through existing dialysis delivery models and at a scale that has not previously been possible.”
